AKTX
Income statement / Annual
Last year (2023), Akari Therapeutics, Plc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Akari Therapeutics, Plc's net income was -$10.01 M.
See Akari Therapeutics, Plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$4,000.00 |
$3,708.00 |
$4,126.00 |
$8,907.00 |
$19,205.00 |
$35,848.00 |
$42,400.00 |
$39,772.00 |
$10,159.00 |
$0.00 |
| Gross Profit |
-$4,000.00 |
-$3,708.00 |
-$4,126.00 |
-$8,907.00 |
-$19,205.00 |
-$35,848.00 |
-$42,400.00 |
-$39,772.00 |
-$10,159.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$12.13 M
|
$9.56 M
|
$9.13 M
|
$12.19 M
|
$16.65 M
|
$15.59 M
|
$23.29 M
|
$17.31 M
|
$5.80 M
|
$6.42 M
|
| General & Administrative
Expenses |
$11.36 M
|
$13.53 M
|
$8.08 M
|
$7.91 M
|
$8.22 M
|
$10.90 M
|
$11.67 M
|
$9.94 M
|
$5.50 M
|
$3.76 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$11.36 M
|
$13.53 M
|
$8.08 M
|
$7.91 M
|
$8.22 M
|
$10.90 M
|
$11.67 M
|
$9.94 M
|
$5.50 M
|
$3.76 M
|
| Other Expenses |
-$6.68 M |
$802,792.00 |
-$27,482.00 |
-$22,007.00 |
$19,000.00 |
-$2.68 M |
-$13,394.00 |
-$43,969.00 |
-$44,224.00 |
$0.00 |
| Operating Expenses |
$16.81 M |
$23.89 M |
$17.21 M |
$20.10 M |
$24.89 M |
$23.80 M |
$34.96 M |
$27.25 M |
$11.30 M |
$10.18 M |
| Cost And Expenses |
$16.81 M |
$23.09 M |
$17.21 M |
$20.10 M |
$24.89 M |
$23.80 M |
$34.96 M |
$27.25 M |
$11.30 M |
$10.18 M |
| Interest Income |
$82,000.00 |
$45,944.00 |
$10,600.00 |
$13,000.00 |
$5,000.00 |
$222,256.00 |
$175,393.00 |
$143,195.00 |
$20,705.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$9.15 M |
$3.05 M |
$0.00 |
| Depreciation &
Amortization |
$4,000.00
|
$3,708.00
|
$4,126.00
|
$8,907.00
|
$19,205.00
|
$35,848.00
|
$42,400.00
|
$39,772.00
|
$10,162.00
|
$8,000.00
|
| EBITDA |
-$16.80 M
|
-$23.08 M
|
-$17.21 M
|
-$20.44 M
|
-$24.73 M
|
-$16.43 M
|
-$35.36 M
|
-$27.25 M
|
-$19.28 M
|
-$10.19 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$6.80 M
|
$5.34 M
|
-$210,101.00
|
$899,357.00
|
-$142,671.00
|
-$507,925.00
|
$2.38 M
|
$9.11 M
|
-$14.72 M
|
$567,569.00
|
| Income Before Tax |
-$10.01 M |
-$17.75 M |
-$17.42 M |
-$20.45 M |
-$24.75 M |
-$23.50 M |
-$32.57 M |
-$18.14 M |
-$45.32 M |
-$9.65 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$10.78 M |
$182,619.00 |
-$2.86 M |
-$2.99 M |
-$3.55 M |
-$4.65 M |
-$43,969.00 |
$3.01 M |
$0.00 |
| Net Income |
-$10.01 M |
-$6.97 M |
-$17.61 M |
-$17.60 M |
-$21.76 M |
-$19.95 M |
-$27.92 M |
-$18.14 M |
-$45.32 M |
-$9.65 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.04 |
-2.23 |
-8.2 |
-11.14 |
-23.77 |
-1.26 |
-2.24 |
-1.54 |
-5.32 |
-11.28 |
| EPS Diluted |
-2.04 |
-2.23 |
-8.2 |
-11.14 |
-23.77 |
-1.26 |
-2.24 |
-1.54 |
-5.32 |
-11.28 |
| Weighted Average Shares
Out |
$4.89 M
|
$3.12 M
|
$2.15 M
|
$1.58 M
|
$915,499.00
|
$15.81 M
|
$12.47 M
|
$11.78 M
|
$8.52 M
|
$855,156.00
|
| Weighted Average Shares
Out Diluted |
$4.89 M
|
$3.12 M
|
$2.15 M
|
$1.58 M
|
$915,499.00
|
$15.81 M
|
$12.47 M
|
$11.78 M
|
$8.52 M
|
$855,156.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
